EBIM
CRL icon

Eagle Boston Investment Management’s Charles River Laboratories CRL Stock Holding History

Eagle Boston Investment Management’s Portfolio CRL Stock Details CRL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		$1.16M Sell
8,146
-19,950
-71% -$2.71M 1.32% 29
2019
Q1 		$4.08M Sell
28,096
-9,815
-26% -$1.29M 1.78% 7
2018
Q4 		$4.29M Sell
37,911
-69,684
-65% -$8.72M 1.49% 14
2018
Q3 		$14.5M Buy
107,595
+2,202
+2% +$272K 1.3% 22
2018
Q2 		$11.8M Buy
105,393
+8,598
+9% +$930K 1.09% 37
2018
Q1 		$10.3M Buy
96,795
+5,493
+6% +$592K 1.03% 42
2017
Q4 		$9.99M Buy
91,302
+4,884
+6% +$531K 1% 40
2017
Q3 		$9.41M Buy
86,418
+1,918
+2% +$197K 0.97% 48
2017
Q2 		$8.55M Sell
84,500
-193
-0.2% -$17.8K 0.93% 47
2017
Q1 		$7.62M Buy
84,693
+4,300
+5% +$365K 0.85% 53
2016
Q4 		$6.13M Buy
80,393
+37
+0% +$2.81K 0.73% 64
2016
Q3 		$6.7M Buy
80,356
+643
+0.8% +$53.9K 0.86% 52
2016
Q2 		$6.57M Buy
79,713
+1,992
+3% +$164K 0.89% 50
2016
Q1 		$5.9M Buy
77,721
+2,445
+3% +$181K 0.82% 56
2015
Q4 		$6.05M Sell
75,276
-3,458
-4% -$249K 0.85% 54
2015
Q3 		$5M Buy
78,734
+3,038
+4% +$218K 0.67% 70
2015
Q2 		$5.32M Sell
75,696
-29,929
-28% -$2.21M 0.67% 71
2015
Q1 		$8.38M Sell
105,625
-44,968
-30% -$3.32M 0.7% 58
2014
Q4 		$9.58M Sell
150,593
-46,968
-24% -$2.94M 0.63% 76
2014
Q3 		$11.8M Sell
197,561
-7,682
-4% -$440K 0.65% 59
2014
Q2 		$11M Sell
205,243
-5,982
-3% -$328K 0.55% 80
2014
Q1 		$12.7M Sell
211,225
-10,976
-5% -$640K 0.63% 71
2013
Q4 		$11.8M Buy
222,201
+64,697
+41% +$3.25M 0.57% 69
2013
Q3 		$7.28M Sell
157,504
-2,988
-2% -$137K 0.44% 83
2013
Q2 		$6.58M Buy
+160,492
New +$6.88M 0.44% 88

Other funds holding CRL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return

Eagle Boston Investment Management's CRL Position: Q2 2019 in Review

Eagle Boston Investment Management reduced its Charles River Laboratories (CRL) stake by 71% in Q2 2019, selling an estimated $2.71M and leaving 8,146 shares worth $1.16M. The position accounts for 1.32% of the portfolio, ranked #29.

Eagle Boston Investment Management first reported a position in CRL in Q2 2013 and has held it in 25 quarters since. The position peaked at $14.5M in Q3 2018. 405 funds tracked by Wall St. Rank hold CRL as of Q2 2019.

  • Eagle Boston Investment Management held 8,146 shares of Charles River Laboratories worth $1.16M as of Q2 2019.
  • Eagle Boston Investment Management sold 19,950 Charles River Laboratories shares in Q2 2019, an estimated $2.71M.
  • Charles River Laboratories made up 1.32% of Eagle Boston Investment Management's portfolio in Q2 2019, its #29 holding.
  • Eagle Boston Investment Management first reported a position in Charles River Laboratories in Q2 2013 and has held it in 25 quarters since.
  • Eagle Boston Investment Management's Charles River Laboratories position peaked at $14.5M in Q3 2018.
  • 405 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2019.

Based on Eagle Boston Investment Management's 13F filing for Q2 2019, filed 5 Aug 2019.